Remdesivir, an antiviral medication, may benefit patients who are infected with mild or moderate forms of COVID-19 infection. Several research findings have suggested the safety and efficacy of remdesivir for a five- to 10-day course with mild adverse reactions. However, larger RCTs are still required to assess its long-term effects.

This systematic review acknowledges some limitations.

First, several potentially relevant clinical trials were excluded from this review, as their final results were still pending when our initial search of articles was conducted.

Moreover, the lack of uniform methodology and follow-up between the studies was a setback to the comparability of our findings, as it did not allow for quantitative analysis.

Read More